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RiVax is a recombinant protein that is currently under clinical
development as part of a human vaccine to protect against
ricin poisoning. RiVax includes ricin A-chain (RTA) residues
1–267 with two intentional amino-acid substitutions, V76M
and Y80A, aimed at reducing toxicity. Here, the crystal
structure of RiVax was solved to 2.1 A ˚ resolution and it was
shown that it is superposable with that of the ricin toxin A-
chain from Ricinus communis with a root-mean-square
deviation of 0.6 A ˚ over 258 C
  atoms. The RiVax structure is
also compared with the recently determined structure of
another potential ricin-vaccine immunogen, RTA 1–33/44–198
R48C/T77C. Finally, the locations and solvent-exposure of two
toxin-neutralizing B-cell epitopes were examined and it was
found that these epitopes are within or near regions predicted
to be involved in catalysis. The results demonstrate the
composition of the RiVax clinical material and will guide
ongoing protein-engineering strategies to develop improved
immunogens.
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1. Introduction
Ricin is a heterodimeric ribosome-inactivating protein (RIP)
that is available worldwide in ton quantities as a byproduct of
castor-oil production from the plant Ricinus communis.T h e
potent cytotoxicity of ricin may be beneﬁcial for chemo-
therapy in humans, but has also been associated with misuse
for political assassination, suicide and chemical warfare
(Millard & LeClaire, 2007). The median lethal dose of ricin is
in the range 1–10 mgk g
 1 if administered to laboratory
animals parenterally or by inhalation; recent work in vitro
suggests that it may be possible to enhance the potencyof ricin
by genetic engineering (Olson et al., 2004). A dose-dependent
latent period of 4–24 h after poisoning limits prompt diagnosis
of ricin exposure, and irreversible toxin internalization by
target cells renders post-exposure therapeutic intervention
difﬁcult. There is no approved antidote or treatment, but
vaccination offers a practical prophylactic strategy to protect
selected populations at risk of ricin exposure.
The crystal structure of the ricin A-chain (RTA; Rutenber et
al., 1991) has served as the starting point for several promising
vaccine concepts (Compton et al., 2011; Marsden et al., 2005;
Olson et al., 2004; Vitetta et al., 2006). In addition to vaccine
development, there is interest in identifying structural corre-
lates of ricin immunity to modulate the humoral immune
response and extend the clinical use of RTA in ligand-targeted
therapy (Chrunyk et al., 1993; Sharp et al., 2009; Smallshaw et
al., 2002).
RTA is an efﬁcient N-glycosidase that catalyzes the
hydrolysis of a speciﬁc adenine within the 28S rRNA of the
60S ribosomal subunit, leading to cell death. The hydrolysisreaction catalyzed by RTA is thought to proceed via a disso-
ciative mechanism with an oxocarbenium transition state
(Roday et al., 2004). Glu177 in the active site stabilizes the
developing positive charge on the substrate ribosyl ring, while
Tyr80 and Tyr123 have been proposed to activate the leaving
group by  -stacking with the adenine (Ghanem et al., 2009).
The enzymatic activity of RTA is the primary source of toxi-
city and therefore must be attenuated for safe vaccine devel-
opment; this can be achieved by the introduction of a single
point mutation, Y80A (Smallshaw et al., 2002).
Based upon clinical observations and laboratory studies, it
has been proposed that RTA harbors a second potential type
of toxicity for humans that stems from a speciﬁc tripeptide
sequence, Leu74-Asp75-Val76 (Smallshaw et al., 2002); this
peptide has been associated with pulmonary vascular leak
syndrome (VLS) and has been referred to as the vascular leak-
inducing peptide (VLP). While VLS is not observed in all
laboratory animal models, the syndrome was dose-limiting in
human chemotherapy trials and consequently is of concern for
optimizing vaccine safety. Disruption of the VLP by a V76M
mutation was shown to prevent RTA-induced weight loss, a
biological marker of VLS, in speciﬁc animal models (Small-
shaw et al., 2002).
The RiVax immunogen is a double mutant of RTA that
combines the Y80A mutation to inactivate catalysis with the
V76M mutation to ensure the removal of any trace VLS
activity from the immunogen. When properly stabilized and
formulated with an adjuvant, RiVax elicited a protective
humoral immune response in laboratory mice and safely
induced ricin-protecting antibodies in human volunteers
during Phase 1 clinical trials (Marconescu et al., 2010; Small-
shaw et al., 2002; Vitetta et al., 2006).
We designed and tested an alternative immunogen platform
called RTA 1–33/44–198 (an RTA variant containing residues
1–198 with a deletion of loop residues 34–43), with the goal of
limiting undesirable protein denaturation and aggregation by
selective deletion of amino-acid residues from RTA that pack
with the ricin B-chain (RTB) in the folded ricin heterodimer
(McHugh et al., 2004; Olson et al., 2004). We have recently
shown that RTA 1–33/44–198 can be stabilized further by the
introduction of speciﬁc disulﬁde bonds (Compton et al., 2011)
and can fold into an immunoreactive form with numerous
mutations in the VLP site (C. B. Millard, unpublished data).
Both RiVax (Smallshaw et al., 2005, 2007) and RTA 1–33/44–
198 (Olson et al., 2004) elicit neutralizing antibodies that
protect animals against ricin exposure, but may differ in their
complement of epitopes.
To characterize RiVax produced from a large-scale manu-
facturing run and compare it with RTA and related immu-
nogens, we here present its X-ray crystal structure to 2.1 A ˚
resolution (deposited as PDB entry 3srp). We discuss the
effects of the Y80A/V76M mutations and the structural
integrity of two neutralizing B-cell epitopes formed by resi-
dues Asn97–Phe108 or Leu161–Ile175, as well as an adjacent
human T-cell epitope formed by residues Ile175–Glu185. We
also compare RiVax with our recently determined X-ray
structure of a synthetically stabilized RTA-based immunogen
called RTA 1–33/44–198 R48C/T77C (PDB entry 3lc9).
Comparison of the two immunogens with their parent mole-
cule, RTA, permits us to assess the structural effects of the
VLS substitutions, as well as the truncation of C-terminal
residues 199–267, on the secondary structure of the human T-
cell epitope formed by residues Ile175–Glu185.
2. Materials and methods
RiVax was obtained from a 100 l Escherichia coli fermentation
and puriﬁed essentially as described by Smallshaw and
coworkers (Peek et al., 2007; Smallshaw et al., 2002). The
protein was stored as a stock at 253 K in 10 mM histidine pH
6.0, 140 mM sodium chloride and 50% glycerol (a stabilizing
excipient). The glycerol was removed by dialysis against 4 l
75 mM Tris–HCl pH 8.0, 1 mM EDTA at 277 K. Dithiothreitol
was added to a ﬁnal concentration of 5 mM using a 1.0 M
stock. Crystals were grown by the hanging-drop method using
a 1:1 ratio of protein (2.8 mg ml
 1) to precipitant. The preci-
pitant used was 30% ammonium sulfate containing 50 mM
sodium acetate pH 4.2. Crystals appeared within 24 h. Crystals
were soaked in Crystal Screen Cryo (Hampton Research,
Aliso Viejo, California, USA) solution No. 20 [0.16 M
ammonium sulfate, 0.08 M sodium acetate trihydrate pH 5.0,
20%(w/v) PEG 4000, 20%(w/v) glycerol] and ﬂash-frozen in
liquid nitrogen. Diffraction data were collected with a Bruker
FR591 high-ﬂux rotating-anode X-ray diffractometer
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Table 1
X-ray crystallography data-collection and reﬁnement statistics.
Values in parentheses are for the outermost data shell.
Space group P41212
Unit-cell parameters (A ˚ ) a = b = 66.56, c = 136.72
Wavelength (A ˚ ) 1.54
Resolution range (A ˚ ) 68.36–2.14 (2.23–2.14)
Unique reﬂections 17463 (1763)
Rmerge† 0.0988 (0.3993)
hI/ (I)i 21.1 (4.4)
Completeness (%) 98.5 (87.4)
Multiplicity 12.4 (6.1)
Reﬁnement statistics
Resolution (A ˚ ) 59.9–2.1
No. of reﬂections 16508
R factor‡ 0.217
Rfree§ 0.254
No. of atoms
Protein 2064
Solvent 151
Other 10
Average B factors (A ˚ 2)
Protein 16.3
Solvent 21.6
R.m.s.d.s from ideal geometry
Bond lengths (A ˚ ) 0.008
Bond angles ( ) 0.980
Ramachandran plot
Most favored regions (%) 92.6
Additional allowed regions (%) 7.4
Generously allowed regions (%) 0.0
Disallowed regions (%) 0.0
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.‡ R factor = P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj.§ Rfree was calculated for a test set consisting of
5% of the total reﬂections.(PROTEUM) and a SMART 6000 2K CCD detector. Initial
phases were calculated using the structure of RTA. The
structure was solved by molecular replacement using AMoRe
(Navaza, 2001). Simulated annealing was carried out with CNS
v.1.1 (Bru ¨nger et al., 1998). The model was reﬁned using
REFMAC5 (Murshudov et al., 2011)
and model building and solvent
addition was performed with Coot
(Emsley & Cowtan, 2004).
3. Results and discussion
We ultimately seek to optimize the
structure of RTA to arrive at cost-
effective recombinant immunogens
that are sufﬁciently stable for
prolonged storage and ﬁeld trans-
port, fully safe for human use and can
most efﬁciently elicit a high fraction
of protective antibodies. Toward this
goal, we compared the RiVax crystal
structure with those of two closely
related ricin vaccine immunogens:
native RTA and a truncated RTA 1–
33/44–198 derivative. The reﬁnement
statistics for RiVax are shown in
Table 1. The X-ray crystal structure
can be superposed onto that of RTA
with a root-mean-square deviation
(r.m.s.d.) of 0.6 A ˚ over 258 C  atoms,
demonstrating that the Y80A and
V76M mutations found in RiVax do
not signiﬁcantly perturb the overall
protein fold or alter the conformation
of residues corresponding to known
neutralizing epitopes. Neither the
active-site mutation (Y80A) nor the
VLS mutation (V76M) signiﬁcantly
alters the side-chain conformations of
adjacent residues.
The immunization of laboratory
animals or humans with RTA or its
derivatives generates a mixture of
high-avidity antibodies, only some of
which are capable of neutralizing the
ricin toxin using in vitro or ex vivo
assays (Lemley et al., 1994; Madda-
loni et al., 2004; Mantis et al., 2006;
Neal et al., 2010; O’Hara et al., 2010).
It is important to qualify our struc-
tural analysis with the point that RTA
epitopes shown to be involved in
toxin neutralization in vitro do not
necessarily correlate with protection
in vivo from ricin poisoning. We limit
our discussion, therefore, to a few
speciﬁc examples of ricin-neutralizing
monoclonal antibodies (MAb) isolated from mouse or human
sera for which the target epitopes have been characterized
using peptide mapping or molecular modeling (Castelletti et
al., 2004; Lebeda & Olson, 1999; Lemley et al., 1994; Neal et al.,
2010; Table 2).
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Figure 1
Comparison of the structures of RiVax, ricin holotoxin and the RTA 1–33/44–198 R48C/T77C
immunogen. (a) Stereoview of the RiVax structure showing the two B-cell epitopes at Asn97–Phe108
and Leu161–Ile175 and the T-cell epitope at Ile175–Glu185. The Asn97–Phe108 epitope bound by the
UNIVAX 70/138 antibody is shown in magenta. The Leu161–Ile175 epitope bound by human
neutralizing antibodies characterized by Castelletti et al. (2004) is shown in green. The Ile175–Glu185
T-cell epitope is shown in blue. The active-site residues within this epitope, Glu177 and Arg180, are
shown as sticks; Tyr123, another active-site residue, is shown as dark gray sticks. The active-site
mutation, Y80A, is shown in cyan. The mutation to the VLS site, V76M, is shown in orange. (b)
Structure of the ricin AB toxin determined by Rutenber et al. (1991) (PDB entry 2aai). The A-chain is
depicted by ribbons and the B-chain by tubes. Lactose (colored red) is reversibly bound to the
carbohydrate-binding site. The N-linked sugars resolved at the glycosylation sites Asn95 and Asn135
are shown as yellow sticks. The putative immunological epitopes are colored as in (a). (c) Structure of
the RTA 1–33/44–198 R48C/T77C disulﬁde-bonded variant based upon PDB entry 3lc9 (Compton et
al., 2011). The epitopes and VLS site are colored as in (a). The helix–turn–helix motif between residues
Ile175 and Glu185 (blue) is found to be fully helical in the 1–33/44–198 R48C/T77C variant. (d)
Mapping of residues which are believed to be important in T-cell activation (Castelletti & Colombatti,
2005; shown in cyan) onto the helical segment between Ile175 and Glu185. Residues which do not
affect T-cell activation when mutated to alanine are shown in blue. One residue, Arg180, had an
intermediate affect on T-cell activation (purple). The ﬁgures were produced using PyMOL (DeLano,
2002).One of the most potent neutralizing antibodies produced
against RTA, called UNIVAX 70/138 (or R70), recognizes a
solvent-exposed loop–helix–loop segment anchored by two  -
strands between residues Asn97 and Phe108 (Lemley et al.,
1994; Fig. 1). The protective effects of some toxin-neutralizing
antibodies can be explained by the functional location of their
epitopes; for example, protective antibodies produced against
the cell-binding domain of Diphtheria toxin may neutralize the
toxin by physically preventing the B-chain from binding to the
target cell surface (Pappenheimer et al., 1972). RTB is known
to contain a binding domain that binds to cell surface glyco-
proteins or glycolipids containing galactose, thereby facil-
itating toxin uptake (Fig. 1b, based on PDB entry 2aai;
Rutenber et al., 1991; Ganguly & Mukhopadhyay, 2006). An
examination of the 2aai crystal structure shows that the RTA
epitope recognized by UNIVAX 70/138 is distant from RTB
and its carbohydrate-binding sites, suggesting that this MAb
does not neutralize ricin toxin by a direct steric effect on the
lectin function of the toxin. The conformation of the structural
region comprising RTA 99–106 has been discussed previously
as an important epitope for generation of toxin-neutralizing
antibodies (Lebeda & Olson, 1999) and substitutions that
perturb this helix have been reported to modulate the catalytic
activity of RTA directly in the
absence of RTB (Olson et al.,
2004).
Another murine MAb called
GD-12 has been characterized
that can neutralize toxin in vitro
and protect mice against intra-
peritoneal or intragastric ricin
exposure (Neal et al., 2010). The
GD-12 binding site is located
near RTA residues Thr163–
Met174 (TLARSFIICIQM) and
overlaps with a human neutra-
lizing B-cell epitope between
residues Leu161 and Ile175
(Castelletti et al., 2004). Exam-
ination of the GD-12 epitope in
the X-ray crystal structures
suggests that unlike UNIVAX
70/138, the binding site for GD-
12 is partially buried in the
folded protein (Fig. 2).
The human B-cell neutralizing
epitope identiﬁed at Leu161–
Ile175 localizes to a helix–turn–
helix (HTH) motif formed by
helices 5 and 6 in RTA (Fig. 1).
The HTH motif also encom-
passes an immunodominant
human T-cell epitope, Ile175–
Glu185, recognized by isolated
T-cell clones (Castelletti &
Colombatti, 2005). The HTH
contains a type I reverse turn
between Phe181 and Ile184 which connects the two anti-
parallel helices of RiVax. In contrast to RiVax or RTA, the
crystal structure of the RTA 1–33/44–198 R48C/T77C immu-
nogen reveals that truncation of the C-terminus converts the
HTH into a helical segment. The segment between Ile175 and
Glu185 has not previously been shown to be able to form a
helix; its secondary structure appears to be dependent upon
other motifs in the C-terminal 199–267 residues.
The secondary structure of the Ile175–Glu185 segment may
be an important structural determinant for peptide presenta-
tion on MHC molecules (Castelletti & Colombatti, 2005). The
identiﬁcation of this T-cell epitope has facilitated a strategy to
circumvent an immune response to RTA-based chemother-
apeutics by using altered peptide ligands which can modulate
T-cell receptor afﬁnities and subsequent T-cell activation
(Adorini, 1993; Castelletti & Colombatti, 2005). In Fig. 1(d),
the cyan-colored residues correspond to those which signiﬁ-
cantly reduce T-cell activation and are likely to bind to the
T-cell receptor. These residues localize to one face of the helix
found in the 1–33/44–198 R48C/T77C structure and include
the hydrophobic residues Ile175, Ala179, Phe181 and Tyr183.
Castelletti and coworkers reported smaller effects on T-cell
activation for the S176A, R180A, I184A and E185A variants.
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Figure 2
Surface representation of RiVax showing the exposure of each epitope. Colors for each epitope are the same
as in Fig. 1(a).
Table 2
Regions of RTA structure potentially involved in MAb binding.
RTA
residues
Active-site residues or
residues involved in
substrate binding
Predicted
unfolding
regions†
B- or T-cell
epitope(s)
Neutralizing
antibody
Residues important in
T-cell activation‡
1–117 Tyr80, Asp96 34–46 — — —
80–100 Tyr91–Thr116
(Asn97–Phe108)
Mouse IgG1
(UNIVAX 70/138)
—
118–210 Tyr123, Glu177,
Arg180
130-160 Leu161–Ile175 Human IgG —
Thr163–Met174 Mouse IgG1
(GD-12§)
—
Ile175–Glu185 — Ile175, Glu177, Phe181,
Gln182, Tyr183, Glu185
211–276 — — — — —
† RTA regions proposed to be involved in the early stages of unfolding for residues 1–198 are based on previously published
studies using molecular-dynamics and coarse-grain simulations (Compton et al., 2011). ‡ Residues identiﬁed by Castelletti &
Colombatti (2005). § Monoclonal antibody described by Roday et al. (2004).These mostly hydrophilic residues localize to the opposite face
of the helix and may bind the MHC molecule (Kurata &
Berzofsky, 1990; Sette et al., 1989). While this segment of the
protein has not previously been shown to be helical in RiVax
or RTA, the helix observed in the RTA 1–33/44–198 variant
may help to identify additional mutations to create altered
peptide ligands.
Finally, we observe that essentially all biologically relevant
B-cell and T-cell epitopes identiﬁed in RTA to date coincide
with regions of the enzyme containing residues involved in
substrate binding or catalysis. The active-site residue Glu177
localizes to a characterized T-cell epitope important in T-cell
activation (Castelletti & Colombatti, 2005). Asp96 also inter-
acts with a portion of the substrate (PDB entry 3hio; Hazes &
Dijkstra, 1988). In the current model of subcellular trafﬁcking
of ricin, the toxin is endocytosed and the protein is transported
to the Golgi and then to the endoplasmic reticulum (ER;
Wesche, 2002). RTA is released from RTB, perhaps by
reduction of a linking disulﬁde. RTA then unfolds and dislo-
cates into the cytoplasm (Clarke & Fersht, 1993). The ribo-
some substrate of RTA resides within the target cell
cytoplasm, to which antibodies would not easily have access.
Binding of toxin-neutralizing antibodies is most likely to
interfere with the steps preceding or following endocytosis;
for example, RTA may need to undergo a particular confor-
mational change during toxin binding to the target cell surface
or to expose a surface which interacts with proteins that
protect against lysosomal degradation (Moisenovich et al.,
2004); alternatively, antibodies might alter binding with a
functional post-translational modiﬁcation (e.g. an ADP-ribo-
sylated amino acid; Glowacki et al., 2002). Future structure-
based studies of ricin-neutralizing antibodies are required to
carefully test whether and how binding or occluding the RTA
active site may perturb the complex process of toxin inter-
nalization and function.
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